Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Impedimed Limited ( (AU:IPD) ).
Impedimed Limited announced the issuance of 17,250,000 unquoted equity securities under an employee incentive scheme, which are not intended to be quoted on the ASX. This move could potentially strengthen the company’s employee engagement and retention strategies, while also impacting its financial structure and market positioning.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.07 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
Impedimed Limited operates in the medical technology industry, focusing on developing and providing non-invasive medical devices and software solutions. The company’s primary products are designed for the assessment and monitoring of fluid status and body composition, with a particular emphasis on applications in healthcare settings such as hospitals and clinics.
YTD Price Performance: -5.77%
Average Trading Volume: 2,138,458
Technical Sentiment Signal: Sell
Current Market Cap: A$99.77M
See more data about IPD stock on TipRanks’ Stock Analysis page.